A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor‐β and vascular endothelial growth factor signalling
Liver International2012Vol. 33(4), pp. 504–515
Citations Over TimeTop 10% of 2012 papers
Yuqing Liu, Zhuo Wang, Jianing Wang, Wingchi Lam, Shuqin Kwong, Furong Li, Scott L. Friedman, Shuyan Zhou, Qi Ren, Zhengshuang Xu, Xingen Wang, Ling Ji, Shoubin Tang, Hui Zhang, Eric Lik Hang Lui, Tao Ye
Abstract
Our findings revealed a novel role of largazole in the treatment of liver fibrosis. Through multiple mechanisms, largazole could be a potentially effective antifibrotic agent.
Related Papers
- → The histone deacetylase-3 complex contains nuclear receptor corepressors(2000)378 cited
- → Nuclear receptor co-repressors are required for the histone-deacetylase activity of HDAC3 in vivo(2013)194 cited
- → Inhibition of Class IIb Histone Deacetylase Significantly Improves Cloning Efficiency in Mice1(2010)112 cited
- → Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma(2018)18 cited
- Arabidopsis thaliana histone deacetylase 1 （AtHD1） is localized in euchromatic regions and demonstrates histone deacetylase activity in vitro(2006)